Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 1.86B 1.63B 1.51B 1.39B 2.63B 178B 2.68B 18.03B 7.06B 87.25B 6.97B 6.82B 302B P/E 2026 *
-13.3x
P/E 2027 * -12x
Enterprise Value 1.86B 1.63B 1.51B 1.39B 2.63B 178B 2.68B 18.03B 7.06B 87.25B 6.97B 6.82B 302B EV / Sales 2026 *
41.7x
EV / Sales 2027 * 31.9x
Free-Float
99.42%
Yield 2026 *
-
Yield 2027 * -
1 day-4.60%
1 week-9.21%
Current month-9.17%
1 month+20.54%
3 months+25.74%
6 months-7.34%
Current year+40.18%
1 week 20.92
Extreme 20.925
24.98
1 month 17.38
Extreme 17.38
25.22
Current year 13.69
Extreme 13.69
25.77
1 year 4.12
Extreme 4.12
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2019
Chief Tech/Sci/R&D Officer - 16/03/2026
Chief Operating Officer 54 28/02/2021
Director TitleAgeSince
Director/Board Member 55 31/12/2019
Director/Board Member 49 31/03/2020
Director/Board Member 57 31/05/2020
Date Insider Type Main position Quantity % Market Cap.
07-05Fiscal year

Chief Technology Officer

18,000 0.0213%
06-30
NEA Management Co. LLC
OthersCompany -1,030,000 1.2192%
06-29Fiscal year

Chief Technology Officer

16,221 0.0192%
Change 5-day change 1-year change 3-year change Capi.($)
-4.60%-9.21%+325.97%+204.43% 1.95B
+0.44%+2.51%+4.36%+10.27% 50.73B
-1.57%-2.80%+383.82%+582.81% 39.73B
-0.14%+0.25%+27.49%-5.23% 34.69B
+1.76%+2.12%+21.44%+58.27% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-3.38% - - 16.8B
-1.49%-4.92%+63.89%+119.25% 15.37B
+0.78%+0.20%+14.69%+17.08% 13.78B
-0.97%-4.02%+10.35%-31.69% 12.85B
Average -0.63%-1.36%+94.99%+109.65% 24.59B
Weighted average by Cap. +0.01%-0.41%+83.68%+123.70%

Financials

2026 *2027 *
Net sales 44.48M 39.07M 36.23M 33.32M 62.94M 4.25B 64.3M 432M 169M 2.09B 167M 163M 7.22B 58.17M 51.1M 47.39M 43.57M 82.31M 5.56B 84.1M 565M 221M 2.73B 218M 214M 9.45B
Net income -167M -147M -136M -125M -237M -16B -242M -1.62B -636M -7.86B -628M -614M -27.17B -193M -170M -158M -145M -274M -18.5B -280M -1.88B -736M -9.09B -727M -711M -31.42B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
187
Date Price Change Volume
13/07/26 US$21.98 -4.60% 1,586,837
10/07/26 US$23.04 -6.04% 1,718,268
09/07/26 US$24.52 +1.91% 1,199,762
08/07/26 US$24.06 -1.39% 1,780,473
07/07/26 US$24.40 +4.95% 1,303,445
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.98USD
Average target price
33.17USD
Spread / Average Target
+50.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock